Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
- Author:
Han Ah LEE
1
;
Young CHANG
;
Pil Soo SUNG
;
Eileen L. YOON
;
Hye Won LEE
;
Jeong-Ju YOO
;
Young-Sun LEE
;
Jihyun AN
;
Do Seon SONG
;
Young Youn CHO
;
Seung Up KIM
;
Yoon Jun KIM
Author Information
- Publication Type:Review
- From:Clinical and Molecular Hepatology 2022;28(3):425-472
- CountryRepublic of Korea
- Language:English
- Abstract: The global burden of chronic liver disease (CLD) is substantial. Due to the limited indication of and accessibility to antiviral therapy in viral hepatitis and lack of effective pharmacological treatment in nonalcoholic fatty liver disease, the beneficial effects of antidiabetics and non–antidiabetics in clinical practice have been continuously investigated in patients with CLD. In this narrative review, we focused on non-antidiabetic drugs, including ursodeoxycholic acid, silymarin, dimethyl4,4’-dimethoxy-5,6,5’,6’-dimethylenedixoybiphenyl-2,2’-dicarboxylate, L-ornithine L-aspartate, branched chain amino acids, statin, probiotics, vitamin E, and aspirin, and summarized their beneficial effects in CLD. Based on the antioxidant, anti-inflammatory properties, and regulatory functions in glucose or lipid metabolism, several non–antidiabetic drugs have shown beneficial effects in improving liver histology, aminotransferase level, and metabolic parameters and reducing risks of hepatocellular carcinoma and mortality, without significant safety concerns, in patients with CLD. Although the effect as the centerpiece management in patients with CLD is not robust, the use of these non-antidiabetic drugs might be potentially beneficial as an adjuvant or combined treatment strategy.
